6185 — Cansino Biologics Share News
0.000.00%
Last trade - 00:00- HK$5.73bn
- HK$4.18bn
- CNY1.06bn
China's CanSino in mRNA vaccine deal with AstraZeneca
Brief: CanSino Biologics Signs Product Supply Framework Agreement With Astrazeneca
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 8.73% - Filing
Brief: CanSino Biologics Gets Approval For Clinical Trial On Tetanus Vaccine
China's CanSino rises as vaccine gets Canada's clinical trial nod
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 10.33% - Filing
Brief: Capital Group's Long Position In H-Shares Of CanSino Falls To 12.62% - HKEX Filing
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 13.99% - HKEX Filing
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 14.61% - Filing
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 15.83% - Filing
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 16.87% - Filing
Brief: JPMorgan's Long Position In H-Shares Of CanSino Falls To 7.26% - HKEX Filing
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 17.86% - Filing
Brief: JPMorgan's Long Position In H-Shares Of CanSino Biologics Falls To 9.96% - HKEX Filing
Brief: CanSino Biologics' COVID Recombinant Vaccine Gets Registration In Hong Kong
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 19.64% - Filing
Brief: CanSino's Bivalent Coronavirus mRNA Vaccine Receives Approval For Clinical Trial
Brief: Capital Group Companies Inc's Long Position In H-Shares Of CanSino Falls To 20.84% - Filing
Brief: JPMorgan's Long Position In H-Shares Of CanSino Rises To 11.53% - HKEX Filing